贝伐珠单抗联合化疗治疗晚期结直肠癌的疗效分析  

Efficacy analysis of Bevacizumab combined with chemotherapy in the treatment of advanced colorectal cancer

作　　者：张惠[1] 时建明[1] 朱凡[1] ZHANG Hui;SHI Jian-ming;ZHU Fan(Department of Medical Oncology,Suzhou Municipal Hospital North District,Suzhou 215000,China)

机构地区：[1]苏州市立医院北区肿瘤内科,215000

出　　处：《中国实用医药》2018年第28期77-79,共3页China Practical Medicine

摘　　要：目的探讨贝伐珠单抗联合化疗治疗晚期结直肠癌的临床疗效。方法 60例晚期结直肠癌患者,随机分为研究组和对照组,各30例。对照组采用单纯化疗治疗,研究组在化疗治疗基础上联合贝伐珠单抗治疗,观察两组患者的近期疗效、平均无进展生存时间、平均总生存期及服用药物期间的安全性。结果研究组疾病控制率为63.3%,高于对照组的36.7%,差异有统计学意义(P<0.05)。研究组平均无进展生存时间与平均总生存期长于对照组,差异有统计学意义(P<0.05)。两组服用药物期间均未出现严重肝肾功能不全、骨髓抑制等不良反应。结论贝伐珠单抗联合化疗治疗可以改善晚期结直肠癌患者预后,延长生存时间,提高治疗疗效。Objective To investigate the clinical efficacy of Bevacizumab combined with chemotherapy in the treatment of advanced colorectal cancer. Methods A total of 60 patients with advanced colorectal cancer were randomly divided into research group and control group, 30 cases in each group. The control group was treated with chemotherapy alone, and the research group was treated with Bevacizumab on the basis of chemotherapy. The short term efficacy, mean progression free survival time, mean overall survival time and safety during medication between the two groups were observed. Results The rate of disease control in the research group was 63.3%, which was significantly higher than 36.7% in the control group, the difference was statistically significant（P0.05）. The mean progression free survival time and the mean overall survival time of the research group were significantly longer than those of the control group, the differences were statistically significant（P0.05）. No adverse reactions such as severe hepatorenal insufficiency and bone marrow suppression occurred in the two groups during the medication period. Conclusion Bevacizumab combined with chemotherapy can improve the prognosis of patients with advanced colorectal cancer, prolong the survival time and improve the therapeutic effect.

关 键 词：贝伐珠单抗 化疗 晚期 结直肠癌 

分 类 号：R735.34[医药卫生—肿瘤]